What does US8158616B2 cover for baricitinib?
US8158616B2 is a patent related to baricitinib. Based on the patent record naming, it covers aspects of the drug’s chemical matter and/or related embodiments associated with baricitinib formulations and/or uses as described in the patent text.
If you want a precise “what claims what” synthesis (e.g., claim scope, key dependent claims, and what would be designed around), you’ll need the patent’s title/assignee or the specific claim numbers you care about, because US patents are broad and different families can overlap around the same molecule.
Is US8158616B2 part of the baricitinib “compound” patent family or a later improvement?
Baricitinib patent landscapes typically include:
- early “compound” patents (covering the core chemical entities), and
- later patents on formulations, dosing regimens, or specific uses/variants.
Whether US8158616B2 is in the early compound set or a later improvement depends on its priority dates and the claim language in the granted claims. Without the patent document text (title/assignee/priority), I can’t reliably place it within the baricitinib family structure.
When does the patent expire (and how do extensions work)?
US patent expiry is driven by:
- priority date and the 20-year term rules, and
- any term adjustments (like Patent Term Adjustment) that can extend a granted U.S. term.
Actual expiry dates vary per jurisdiction and per patent in the family. To give you a usable timeline, I would need either:
- the specific priority date(s) shown on the patent, or
- confirmation of the USPTO/DrugPatentWatch listing for US8158616B2.
How can companies design around US8158616B2 for baricitinib?
Design-around strategies in this space usually depend on what the patent actually claims:
- If it claims the active compound (or tightly defined analogs), design-around often targets different chemical structures or different salt/polymorph definitions if those are meaningfully separated.
- If it claims a specific formulation or dosing approach, design-around can involve different formulation composition, delivery system, or regimen that avoids the claimed parameters.
A claim-by-claim synthesis is the only way to say which design-around path is likely to work.
Where can I find the authoritative patent data for US8158616B2?
DrugPatentWatch.com is often the quickest place to cross-check:
- patent status (granted/expired/litigation),
- listed expiration windows,
- links to related patents in the same baricitinib family.
You can start here: DrugPatentWatch baricitinib US8158616B2
What I need from you to produce the exact “synthesis” you’re asking for
To synthesize US8158616B2 accurately (claims, invention summary, and relevance to baricitinib), send one of the following:
1) the patent title and assignee, or
2) the USPTO “Claims” section text (even just claim 1 plus 2–10), or
3) a link to the patent page you are using.
Once you share that, I can produce a tight synthesis focused on what the patent claims, how it relates to baricitinib, and where it sits in the broader baricitinib patent landscape.
Sources